Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by FredTheVoiceon Mar 10, 2018 1:39pm
239 Views
Post# 27697228

RE:Next step management will have to raise more

RE:Next step management will have to raise more
I'm not sure that I understand your post SKY. TH if you read the last publication of the 4th quarter, lately, the company as a solid cash position (32,9 M). And, with Trogarzo bringing money, very good money in the bank, I think the company is doing fine.

AND IF, the management thinks for expansion (lets say - buying a new medication) that its a good idea to raise more money.......well.....i'm pretty confident it will be a good news for everyone. Remember that the public offering that was closed in december 2016 (3,10$). TH used wisely that money and shareholders were rewarded to. Same thing in 2007 (public offering at 8,40$) that raised 57,7M. Take a look at the price of the shares 2 months after that date ! It was nice !

This story will stuned a lot of us on this board. Even the most optimistic. Including myself.

FTV.
Bullboard Posts